Possibly, at odds with the above data, in a retrospective cohort of 437 breast cancer patients categorized according to ER, PR and HER2 receptors, higher levels of TSH were associated with hormone-receptor-positive/HER2-negative cancers compared with hormone-receptor-positive/HER2-positive cancers. This evidence concerns the gene PGR and breast carcinoma.